

MosaiQ AiPlex[®] CTDplus

Connective Tissue Diseases
Microarray Solution

Connective Tissue Diseases



Not available for diagnostic purposes in the US.
Subject to FDA clearance



Designed to provide comprehensive CTD diagnostic insights and workflow efficiency

Autoimmune connective tissue diseases (CTD) are complex disorders that may present with a wide spectrum of non-specific manifestations and its differential diagnosis remain clinically challenging.¹

Our targeted menu covers 15 markers in one panel.²⁻¹⁰

CTD

DFS70/LEDGF Anti-DFS70 confirms specific anti-nuclear antibodies pattern observed in immunofluorescence.

RA

CCP Anti-CCP in combination with other markers can help identify connective disease comorbidity.

SLE

dsDNA, Sm, Sm/RNP, Chromatin, Ribosomal P Anti-Chromatin improves the sensitivity of SLE detection. Anti-Ribosomal P is associated with neuro-psychiatric SLE.

IIM

Jo-1 Anti-Jo-1 are the only autoantibodies included in the current IIM classification criteria.

MCTD

U1RNP and Sm/RNP Anti-U1RNP and anti-Sm/RNP help to differentiate MCTD.

SjS

SS-A (Ro60), SS-B (La), TRIM21 (Ro52) Differentiating anti-SS-A 60 from TRIM21 (Anti-SSA 52) is important as TRIM21 may be associated with interstitial lung disease.

SSc

CENP-B, Scl-70, RNA Pol III These three markers aid the differentiation between diffuse and limited form of SSc.

CTD: Connective Tissue Disease
RA: Rheumatoid arthritis
SLE: Systemic lupus erythematosus
IIM: Idiopathic inflammatory myopathies

MCTD: Mixed connective tissue disease
SjS: Sjögren's syndrome
SSc: Systemic sclerosis

Fast, Easy, Comprehensive MosaiQ AiPlex[®] CTDplus

Includes most of the key markers recommended by clinical guidelines^{2-4, 6, 7}

As the prevalence of autoimmune rheumatic disorders such as RA will continue to grow,¹¹ the demand for highthroughput testing solutions will increase. Autoantibody panels may also help identify common comorbidities within connective tissue diseases.



Generates multiple insights in one report with only 10 µl patient sample. One microarray provides up to 15 individual results.



Reduces hands-on time and storage space with ready to use, concentrated onboard reagents and buffers.



Saves time while avoiding human errors with embedded standardized master curve into the RFID tags of all magazines containing microarrays. Additionally, all reagents are equipped with RFID* tags.



Shares key reagents with other panels, enabling combined autoimmunity, allergy, and further testing.

* RFID: Radio Frequency Identification



MosaiQ AiPlex[®] CTDplus, runs on the MosaiQ platform, is designed to reduce the time to results for patients with CTD.



Simple Workflow

- Patients sample in, result out in one single step
- QC and calibration embedded



Fast Results

- Results within one day
- One sample tube (low volume) for multiple tests



Actionable Insights

- Panels help streamline clinical decision-making for physicians
- Comprehensive panels simplify complex testing pathways

1 Kernder A. Rheumatol Int. 2023;43(8):1453.

2 Aringer M. Ann Rheum Dis. 2019;78:1151.

3 Shiboski CH. Arthritis Rheumatol. 2017;69(1):35.

4 Lundberg IE. Arthritis Rheumatol. 2017;69(12):2271.

5 Alarcón-Segovia D. J Rheumatol. 1989;16(3):328.

6 Tanaka Y. Modern Rheumatology. 2021;31(1):29.

7 van den Hoogen F. Arthritis Rheum. 2013;65(11):2737.

8 Aletaha D. Arthritis Rheum. 2010;62(9):2569.

9 Decker P. Eur J Intern Med. 2021;91:45-52.

10 Mahler M. J Immunol Res. 2014;2014:315179.

11 GBD. Lancet Rheumatol. 2023;5(10):e594-e610



Find out more!

©AliveDx Suisse SA. 2025. The AliveDx logo, AliveDx, MosaiQ, MosaiQ AiPlex, MosaiQ AllergyPlex COMBO and LumiQ are trademarks or registered trademarks of AliveDx group companies in various jurisdictions. Menus and capabilities are subject to change. Not all methods may be available in all territories. Subject to regulatory clearance. This product is not currently available in the USA, cleared or approved by the U.S. Food and Drug Administration (FDA) for clinical use.

AliveDx